Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?
- 240 Downloads
Purpose of Review
Since its initial approval in 1997, rituximab has revolutionized the treatment of CD20-positive lymphoproliferative disorders. Now, over two decades later, second-generation molecules are emerging that may have key biological advantages compared to rituximab, as well as biosimilars that may be more cost-effective. Clinicians, health policy makers, and payers will now need to critically appraise the available evidence for these competitors and decide which anti-CD20 to use.
Evidence has emerged directly comparing rituximab IV to a subcutaneous preparation, and head-to-head comparisons of rituximab versus next-generation anti-CD20 monoclonal antibodies have also been published. Trials comparing rituximab with newly developed biosimilars have also allowed for registration of these agents.
In this review, we will present an overview of anti-CD20 monoclonal antibody development, discuss the mechanistic and clinical evidence for rituximab, as well as the novel compounds, and provide commentary on the possible advantages and limitations of these agents.
KeywordsLymphoma CLL CD20 Monoclonal antibodies Rituximab Immunotherapy Biosimilar
Compliance with Ethical Standards
Conflict of Interest
Ciara L. Freeman has received research funding through grants from Roche and Genentech, has served on advisory boards for AbbVie and Celgene, and has received honoraria for service as a consultant from Seattle Genetics.
Laurie Sehn has received research funding through grants from Roche and Genentech and has received honoraria from Roche, Genentech, Seattle Genetics, AbbVie, Celgene, Amgen, Gilead, TG Therapeutics, Pfizer, Karyopharm, Apobiologix, Lundbeck, and Janssen for service as a consultant.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 5.Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495–7.Google Scholar
- 7.Reff ME. The discovery of rituxan. In: The process of new drug discovery and development. 2nd ed. New York: Informa Healthcare; 2006, ed. C.G.O.D. Smith, J. 2006, New York: Informa Healthcare.Google Scholar
- 9.Pyzik M, et al. FcRn: The architect behind the immune and non-immune functions of IgG and albumin. J Immunol (Baltimore, Md. : 1950). 2015;194(10):4595–603.Google Scholar
- 10.•• Salles G, et al. Rituximab in b-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34(10):2232–73. Comprehensive review of rituximab across all malignant indications written by those involved in the pivotal trials and with extensive experience with this agent. PubMedPubMedCentralGoogle Scholar
- 14.Dakhil S, Hermann R, Schreeder MT, Gregory SA, Monte M, Windsor KS, et al. Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma. Leukemia & Lymphoma. 2014;55(10):2335–40.Google Scholar
- 15.Salar A, et al. Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage. J Clin Oncol: Phase IB Study; 2014.Google Scholar
- 17.Davies A, Merli F, Mihaljević B, Mercadal S, Siritanaratkul N, Solal-Céligny P, et al. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol. 2017;4(6):e272–82.PubMedGoogle Scholar
- 18.Lugtenburg P, Avivi I, Berenschot H, Ilhan O, Marolleau JP, Nagler A, et al. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. Haematologica. 2017;102(11):1913–22.PubMedPubMedCentralGoogle Scholar
- 19.Assouline S, Buccheri V, Delmer A, Gaidano G, Trneny M, Berthillon N, et al. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. Lancet Haematol. 2016;3(3):e128–38.PubMedGoogle Scholar
- 20.Panizo C, et al. Safety of subcutaneous administration of rituximab during the first-line treatment of patients with non-Hodgkin lymphoma: the MabRella study. Blood. 2016;128(22):2971.Google Scholar
- 21.Rummel M, et al. Prefmab: final analysis of patient preference for subcutaneous versus intravenous rituximab in previously untreated CD20+ diffuse large B-cell lymphoma and follicular lymphoma. Blood. 2015;126(23):3972.Google Scholar
- 23.Ponzetti C, et al. Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey. Clinicoecon Outcomes Res. 2016;8:227–33.PubMedPubMedCentralGoogle Scholar
- 26.Wolfromm A, et al. home administration of subcutaneous rituximab is safe and associated with significant cost saving: a single center experience. Blood. 2017;130(Suppl 1):4676.Google Scholar
- 42.Bologna L, Gotti E, Manganini M, Rambaldi A, Intermesoli T, Introna M, et al. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol. 2011;186(6):3762–9.PubMedGoogle Scholar
- 44.Mozessohn L, et al. Rituximab resistant follicular lymphoma: predictors of rituximab resistance, incidence of transformation and prognosis. Blood. 2011;118(21):4981.Google Scholar
- 52.Montillo M, Byrd JC, Hillmen P, O’Brien S, Barrientos JC, Reddy NM, et al. Long-term efficacy and safety in the resonate study: IBRUTINIB in patients with previously treated chronic lymphocytic leukemia (CLL) with up to four years follow-up. Hematol Oncol. 2017;35(S2):235–6.Google Scholar
- 54.Hillmen P, Robak T, Janssens A, Babu KG, Kloczko J, Grosicki S, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet. 2015;385(9980):1873–83.PubMedGoogle Scholar
- 56.Reyes C, et al. Cost-effectiveness analysis of obinutuzumab versus ofatumumab for previously untreated chronic lymphocytic leukemia (CLL). Blood. 2014;124(21):1324.Google Scholar
- 61.Maloney DG, Fukuhara N., Ogura M, Larouche JF, Tournilhac O, Coleman M, Hong X, Fennessy Cota M, Woessner M, Tobinai K. A phase III study of ofatumumab vs rituximab in indolent B-cell non-Hodgkin lymphoma relapsed after rituximab-containing therapy (HOMER): results of the interim analysis in 21st Annual Congress of the European Hematology Association. 2016: Copenhagen, Denmar.Google Scholar
- 65.Umana P, et al. GA101, a novel humanized type II CD20 antibody with glycoengineered Fc and enhanced cell death induction, exhibits superior anti-tumor efficacy and superior tissue B cell depletion in vivo. Blood. 2007;110(11):2348.Google Scholar
- 69.Sehn LH, Goy A, Offner FC, Martinelli G, Caballero MD, Gadeberg O, et al. Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: Final analysis of the GAUSS study. J Clin Oncol. 2015;33(30):3467–74.PubMedPubMedCentralGoogle Scholar
- 71.Goede V, Fischer K., Dyer MJS, Müller L, Smolej L, Di Bernardo MC, Knapp A, Nielsen T, Hallek M Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: final survival analysis of the CLL11 study. in European Hematology Association 2018. EHA Learning Center.Google Scholar
- 75.Casasnovas R-O, et al. Obinutuzumab versus rituximab in combination with ACVBP-14 or CHOP-14 following a PET-driven strategy in Aa-IPI 1-3 DLBCL patients (< 60 years): third planned interim and final analyses of the Gained trial. Blood. 2017;130(Suppl 1):190.Google Scholar
- 76.Vitolo U, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017;0(0):JCO.2017.73.3402.Google Scholar
- 78.Rafiq S, Butchar JP, Cheney C, Mo X, Trotta R, Caligiuri M, et al. Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. J Immunol. 2013;190(6):2702–11.PubMedPubMedCentralGoogle Scholar
- 79.Vitolo U, et al. Obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma: final results from an open-label, randomized phase 3 study (GOYA). Blood. 2016;128(22):470.Google Scholar
- 81.Pott C, et al. Minimal residual disease in patients with follicular lymphoma treated with obinutuzumab or rituximab as first-line induction immunochemotherapy and maintenance in the phase 3 GALLIUM study. Blood. 2016;128(22):613.Google Scholar
- 83.Cramer P, von Tresckow J, Bahlo J, Robrecht S, Langerbeins P, al-Sawaf O, et al. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19(9):1215–28.PubMedGoogle Scholar
- 84.Launonen A, et al. Early disease progression predicts poorer survival in patients with follicular lymphoma (FL) in the GALLIUM study. Blood. 2017;130(Suppl 1):1490.Google Scholar
- 85.Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national LymphoCare study. J Clin Oncol. 2015;33(23):2516–22.PubMedPubMedCentralGoogle Scholar
- 86.Oestergaard MZ, et al. Superiority of obinutuzumab over rituximab in a new molecular follicular lymphoma-like subgroup of DLBCL: results from an exploratory analysis of the phase 3 GOYA trial. Blood. 2017;130(Suppl 1):1543.Google Scholar
- 88.Miller J, et al. Ublituximab (TGTX-1101), a novel anti-CD20 monoclonal antibody (mAb), demonstrates activity in rituximab-sensitive and rituximab–resistant B non-Hodgkin lymphoma (B-NHL) pre-clinical <em>in vitro</em> and <em>in vivo</em> models. Blood. 2012;120(21):2756.Google Scholar
- 90.Sawas A, Farber CM, Schreeder MT, Khalil MY, Mahadevan D, Deng C, et al. A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab. Br J Haematol. 2017;177(2):243–53.PubMedPubMedCentralGoogle Scholar
- 91.Cazin B, et al. Multicentre phase I study with an 8-dose regimen of single agent anti-CD20 monoclonal antibody LFB-R603 in patients with relapsed chronic lymphocytic leukemia (CLL). Blood. 2011;118(21):2862.Google Scholar
- 92.Nastoupil LJ, et al. Tolerability and activity of chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib in patients with advanced CLL and NHL. J Clin Oncol. 2017;35(15_suppl):7511.Google Scholar
- 94.S, G. Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for delivery at the Brookings Institution on the release of the FDA’s Biosimilars Action Plan. 2018; Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm613881.htm.
- 95.The Lancet H. Biosimilars: an optimistic outlook, but vigilance is needed. Lancet Haematol. 2017;4(8):e341.Google Scholar
- 97.Biosimilars in the EU - information guide for healthcare professionals. 2017 [cited 2018 2 SEPT]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.pdf.
- 100.Jurczak W, Moreira I, Kanakasetty GB, Munhoz E, Echeveste MA, Giri P, et al. Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study. Lancet Haematol. 2017;4(8):e350–61.PubMedGoogle Scholar
- 101.Association E.M. Summary of product characteristics: rixathon 2018; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003903/WC500232460.pdf.
- 102.Association E.M. Summary of product characteristics: truxima 2018; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004112/WC500222694.pdf.
- 104.Viswabandya A, et al. Pharmacokinetic and pharmacodynamic evaluation of a biosimilar rituximab in newly diagnosed diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP (rituximab, cyclophosphamide, adriamycin, vincristine, prednisolone). Blood. 2007;110(11):4491.Google Scholar
- 107.Menon H, et al. Pharmacokinetic and pharmacodynamic properties of a biosimilar rituximab (Reditux<sup>®</sup>) are identical to the innovator brand MabThera<sup>®</sup>− experience from a tertiary cancer centre in Western India. Blood. 2014;124(21):2246.Google Scholar
- 109.Organization, W.H. WHO model list of essential medicines: 20th edition. 2017 [cited 2018 2 sept]; Available from: http://apps.who.int/iris/bitstream/handle/10665/273826/EML-20-eng.pdf?ua=1.
- 110.Chopra R, Lopes G. Improving access to cancer treatments: the role of biosimilars. J Global Oncol. 2017;3(5):596–610.Google Scholar